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Abstract
Background: Concomitant with the rise in childhood obesity there has been a significant increase in the number
of adolescents with clinical features of insulin resistance and prediabetes. Clinical insulin resistance and prediabetes
are likely to progress to type 2 diabetes and early atherosclerosis if not targeted for early intervention. There are no
efficacy trials of lifestyle intervention in this group to inform clinical practice. The primary aim of this randomised
control trial (RCT) is to determine the efficacy and effectiveness of two different structured lifestyle interventions
differing in diet composition on insulin sensitivity, in adolescents with clinical insulin resistance and/or prediabetes
treated with metformin.
Methods/design: This study protocol describes the design of an ongoing RCT. We are recruiting 108 (54 each
treatment arm) 10 to 17 year olds with clinical features of insulin resistance and/or prediabetes, through physician
referral, into a multi-centred RCT. All participants are prescribed metformin and participate in a diet and exercise
program. The lifestyle program is the same for all participants except for diet composition. The diets are a high
carbohydrate, low fat diet and a moderate carbohydrate, increased protein diet.
The program commences with an intensive 3 month dietary intervention, implemented by trained dietitians, fol-
lowed by a 3 month intensive gym and home based exercise program, supervised by certified physical trainers. To
measure the longer term effectiveness, after the intensive intervention trial participants are managed by either their
usual physician or study physician and followed up by the study dietitians for an additional 6 months. The primary
outcome measure, change in insulin sensitivity, is measured at 3, 6 and 12 months.
Discussion: Clinical insulin resistance and prediabetes in the paediatric population are rapidly emerging clinical
problems with serious health outcomes. With appropriate management these conditions are potentially reversible
or at least their progression can be delayed. This research study is the first trial designed to provide much needed
data on the effective dietary management for this cohort. This study will inform clinical practice guidelines for
adolescents with clinical insulin resistance and may assist in preventing metabolic complications, type 2 diabetes
and early cardiovascular disease.
Trial registration: Australian and New Zealand Clinical Trials Registration Number ACTRN12608000416392
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Concomitant with the rise in childhood obesity there
has been a significant increase in the number of adoles-
cents with clinical signs of insulin resistance and predia-
betes [1]. It is essential that adolescents with clinical
insulin resistance and prediabetes are targeted for early
intervention. Unmanaged, they are likely to progress to
type 2 diabetes and early atherosclerosis [2]. Develop-
ment of type 2 diabetes in young people is of particular
concern because complications are common and appear
early in the disease [3,4].
Avoidance of progression to type 2 diabetes is of enor-
mous benefit, not only to the individual in terms of
increasing life expectancy and quality of life, but also in
economic terms to society and health care payers [5].
Evidence, primarily from adult studies, indicates that
progression can be reduced by diet, exercise and metfor-
min [5].
Diet
The role of the specific macronutrient content of the
diet in the management of insulin resistance in adoles-
cents has not been previously investigated. Most current
methods of dietary management focus on weight man-
agement and recommend a high carbohydrate, low fat
approach [6]. However, a recent systematic review of
the dietary management of obesity in children and ado-
lescents concluded: “There is a marked mismatch
between the public health importance of childhood obe-
sity and the number and quality of the studies conducted
so far to assess dietary interventions for weight reduction
in childhood and adolescence, and little evidence to sup-
port the current recommendation of a low-fat energy-
restricted diet.”[7]. The effectiveness of a low fat high
carbohydrate dietary pattern over the long term remains
uncertain, and despite widespread dissemination of the
public health message to adopt a low fat high carbohy-
drate diet, rates of obesity, insulin resistance, prediabetes
and type 2 diabetes continue to climb.
One alternative is a moderate carbohydrate, increased
protein diet. In adults, several studies indicate that this
diet may enhance weight loss and improve metabolic
markers including post prandial glucose levels [8-10].
Not all studies support these findings [11], although,
there are several supportive mechanisms proposed. The
relative success of lower carbohydrate, higher protein
diets has been related to i) an increase in satiety [12,13]
ii) effects on thermogenesis, iii) favourable changes in
body composition (preserves fat free mass and reduces
fat mass)[14]; and iv) decreased energy-efficiency, all of
which are related to protein metabolism [15-17]. How-
ever, no clinical trial data are available in children and
adolescents.
Little is known about the optimal dietary intervention
strategy for overweight and obese children and adoles-
cents. Intervention studies have used hypo-caloric diets,
with and without energy based food exchange system
(for example Traffic Light guides), national dietary
guidelines and protein sparing modified fasts, with vary-
ing results [18]. However, many inadequately described
the details of the prescribed dietary intervention, making
replication of the interventions difficult [18]. Structured,
restrictive weight management diets have been also been
described [19]. While there is general concern that this
may be counter productive to the development of
healthy eating habits, anecdotally, many young people
who have successfully lost weight in our Weight Man-
agement Services frequently request dietary prescription.
This observation supports the need for high quality stu-
dies which includes detailed dietary interventions to
inform best practice.
Exercise
Including a physical activity intervention in the manage-
ment of overweight and obese adolescents is considered
to be part of best practice [20]. Physical activity, with or
without dietary intervention, is effective in improving
body composition and may improve insulin sensitivity
and other metabolic markers [21,22]. Most paediatric
studies have used aerobic training; however, evidence
from two small paediatric studies suggests that resistance
training may also be important for improving insulin sen-
sitivity, body composition and fat distribution [23,24].
Metformin therapy
There are now five randomised control trials (RCTs)
[25] that have demonstrated the beneficial effects of
metformin in adolescents with insulin resistance and/or
prediabetes. These results support previous studies
assessing the role of metformin in adolescents with type
2 diabetes, polycystic ovary syndrome and non-alcoholic
fatty liver disease [26-28]. The effect of metformin ther-
apy tends to be small. Results from our systematic
review and meta-analysis indicate that after 6 months of
metformin therapy in children and adolescents with
insulin resistance there was a statistically significant
mean decrease in fasting insulin, homeostasis model
assessment of insulin resistance (HOMA) and body
mass index (BMI) of 9.6 microU/ml (95% CI: 6.3 to
13.0) and 2.7 kg/m
2 (95% CI: 1.7 to 3.6), respectively,
compared to the placebo control group [25]. Results
from studies in adults suggest that a lifestyle change
with pharmacotherapy exceeds the benefit of either
intervention alone [29]. However, no study has evaluated
more intensive lifestyle interventions in conjunction
with metformin in this target group.
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The primary aim of this study is to determine the effi-
cacy of two different structured dietary interventions on
insulin sensitivity, in adolescents with clinical evidence
of insulin resistance and/or prediabetes treated with
metformin. The isocaloric diets are 1) a high carbohy-
drate, low fat diet and 2) a moderate carbohydrate,
increased protein diet.
We hypothesise that the moderate carbohydrate,
increased protein diet will be more effective than the
high carbohydrate diet in improving insulin sensitivity
and metabolic profile in adolescents with clinical fea-
tures of insulin resistance and/or prediabetes.
Design and Methods
Ethics approval
The study has been reviewed and approved by The
Children’s Hospital at Westmead (CHW) Human
Research Ethics Committee (07/CHW/12), Sydney
South West Area Health, Western Zone (08/LPOOL/
195) and Sydney South West Area Health Service,
Royal Prince Alfred Hospital (08/RPAH/455). Written
informed consent from parents and assent from the
young people is sought prior to their enrolment in the
study.
Design
The study is a 12 month RCT, taking place at three ter-
tiary hospitals in Sydney, Australia: CHW (the main
study centre), Royal Prince Alfred Hospital and Camp-
belltown Hospital. The project consists of three phases:
Phase I (0 to 3 months): Intensive structured dietary
intervention
Phase II (4 to 6 months): Intensive exercise program
Phase III (7 to 12 months): Maintenance
The overall schedule for the intervention is shown in
Figure 1.
At the commencement of the study the children and
adolescents are randomised to one of two diets. All par-
ticipants are treated with metformin and receive the
same overall lifestyle intervention. The only difference
between the two treatment arms is the composition of
the diet.
Outcome measures
The primary outcome measure is insulin sensitivity.
Insulin sensitivity is measur e da tb a s e l i n ea n da f t e r
3 and 12 months at CHW by the whole body insulin
sensitivity index derived from an oral glucose tolerance
test (OGTT) using the following formula: 10 000/√
((Fasting insulin × fasting glucose) × (mean 2 hr glucose
× mean 2 hr insulin))[30]. The potential confounding
variables include adiposity and change in adiposity,
pubertal stage, fitness and physical activity and dietary
adherence. The secondary outcome measures are meta-
bolic profile indicators including: acanthosis nigricans
score, amenorrhoea/oligomenorrhoea, blood pressure,
total cholesterol, HDL-cholesterol, triglycerides, waist to
height ratio, hs-CRP, adipokines. Changes in outcome
measures will be examined over time, as will differences
between trial arms.
Participants and recruitment
Approximately 108 (54 in each treatment arm) 10 to
17 year olds with clinical insulin resistance and/or pre-
diabetes are being recruited through doctor referral
from the three tertiary hospitals trial sites in Sydney as
well as local general practitioner (primary care physi-
cian) and paediatrician referral. After a patient has
been assessed and identified as meeting the trial cri-
teria the patient and parent or carer is informed about
the study by the referring doctor or study physician. If
interested in participating, the patient and parent or
carer makes phone contact with the research dietitian
who explains the study design and sends a parent/
carer information sheet and an information sheet for
the adolescent detailing the study researchers, inter-
vention, the potential benefits and required commit-
ment and consent form. Once written consent is
obtained by the study team the participant is rando-
mised to one of two diets.
Selection criteria
Inclusion criteria
Ten to 17 year olds who are overweight or obese, as
defined by the International Obesity TaskForce criteria
[31] with either pre type 2 diabetes as defined by the
American Diabetes Association [32] and/or clinical insu-
lin resistance are eligble for recruitment. Clinical insulin
resistance is defined as overweight or obese and fasting
insulin (pmol/L)/glucose (mmol/L) ratio >20 with one
or more of the following acanthosis nigricans, polycystic
ovarian syndrome (National Institute of Health criteria
[33]), hypertension [34], fasting HDL cholesterol < 1.03
mmol/L [35] or fasting triglycerides ≥ 1.7 mmol/L [35].
Exclusion criteria
Type 1 or type 2 diabetes, contraindications to metfor-
min therapy, secondary causes of obesity, psychiatric
disturbance, significant mental illness, inability to take
part in physical activity, weight loss medications or
medications known to cause weight gain, and weight
>120 kg, due to technical difficulties with dual energy
x-ray absorptiometry machine (DXA). Children and ado-
lescents taking metformin prior to commencement of
the study are required to have a three month wash-out
period.
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Page 3 of 10 Phase I (0 to 3 months) At baseline participants will be randomly assigned to one of two diets and 
commenced on metformin  
High carbohydrate, low fat diet 
(n=54)
Moderate carbohydrate, increased 
protein
(n=54)
Medical consultation 
Dietitian consultation 
Dietitian support
 a
Intensive dietary intervention 
week 0 &12 
week 0, 2, 6 & 12 
week 4 & 9
b
Intensive dietary intervention 
week 0 &12 
week 0, 2, 6 & 12 
week 4 & 9
b
Phase II (4 to 6 months)
Medical consultation 
Gym sessions  
Home based PA 
Dietitian support
a
Dietitian consultation 
Intensive exercise intervention 
Participants will continue with their prescribed diet  
week 26 
twice a week 
once a week 
week 16, 20, & 24 
week 26 
Phase III (7 to 12 months)  
Medical consultation 
Dietitian support
a
Dietitian consultation
Maintenance
Participants will continue prescribed diet and exercise routine 
week  38, 52 
week 32, 38
 b, 44 
week 52
aDietitian will make contact with the families by either phone, email or SMS  
b 24 hour food recall by the research dietitian (via phone) 
Figure 1
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Treatment allocation occurs centrally by minimisation
[36] with the aid of computer software [37] at CHW.
To adjust for potential confounding influences partici-
pants are randomised into dietary groups stratified by
sex, pubertal stage, categorised by the study physician
as either prepubertal or early puberty (Tanner stage 1
and 2) or pubertal (Tanner stage 3, 4 and 5), and BMI
status (overweight or obese as defined by the Interna-
tional Obesity TaskForce [31]).
Sample size
The sample size is based on the primary outcome,
change in whole body insulin sensitivity index (ISI)
between baseline and one year, using means and stan-
dard deviations (SD) from our clinical data [38] and are
consistent with published data [30]. To have an 80%
chance of detecting a significant increase in whole body
ISI over a one year period at the two sided 5% level, 43
young people are required in each intervention arm,
assuming a clinically significant increase in whole body
ISI of 0.8 and an SD of 1.3. The high SD allows for the
variation of insulin sensitivity during puberty. To
accommodate a 20% dropout rate we will need to
recruit 54 in each intervention arm (108 in total). A
20% drop out rate is based on two Australian paediatric
weight reduction trials, PEACH and HELPP, which
reported a 12% and 18% [39] dropout rate at 12 months.
In addition, based on our clinical experience, we antici-
pate a maximum of 2 or 3 participants may progress to
type 2 diabetes. However, treatment for these partici-
pants is likely to be consistent with the study
intervention.
Interventions
At the commencement of the study all participants are
commenced on metformin and randomised to one of
two diets. The participants are encouraged to follow
their prescribed diet for the duration of the trial.
Metformin
Metformin (Diabex) is dispensed through the pharmacy
at CHW and is provided at no cost to all participants.
The initial dose is 250 mg twice a day. After the first
two weeks this is increased to a final dose of 500 mg
twice daily.
Diets
Diet 1 is a high carbohydrate, low fat diet, that is 55-
60% carbohydrate (moderate glycaemic load), 30% fat
(≤ 10% saturated fat) and 15% protein. Diet 2 is a mod-
erate carbohydrate, increased protein diet, that is 40-
45% total energy (moderate glycaemic load), 30% fat (≤
10% saturated fat), 25-30% protein. Both diets are pre-
scriptive and two different energy levels are prescribed
depending upon age: 6,000 to 7,000 kJ (10 to 14 year
old) or 7,000 to 8,000 kJ (15 to 17 year old). Representa-
tive menus for the two diets are shown in Table 1.
Medical care
Clinical progress is reviewed by the participant’s primary
referring physician or study physician at 3, 6, 9 and 12
months, unless otherwise indicated. The physician
assesses pubertal staging, blood pressure, grading of
acanthosis nigricans, menstrual history and metformin
dosage/adherence. The physician is blinded to the trial
arm of the individual and participants are requested to
not inform their physician.
Phase 1: Intensive structured dietary intervention (0 to 3
months)
Phase I assesses the impact of the macronutrient con-
tent of the diet on insulin sensitivity. The trial dietitian
(lifestyle coach) delivers a standardised intervention to
both trial arms, which utilises a prescribed meal plan
and coaching model. Participants are not given the
macronutrient content of the diets; they have been sim-
ply told that they will be randomised to one of two diets
and they are given a meal plan, titled ‘My Meal Plan’.
The meal plans take into consideration adolescent food
preferences, with the aim of weight loss. The coaching
framework provides a theoretical basis for a number of
key psychological variables which are important in
achieving dietary compliance, lifestyle change and sus-
tainable weight loss, such as self efficacy, stage of change
intervention, autonomy, assuming responsibility, self
monitoring, goal setting, accountability and self directed
behaviour change[21,40].
During Phase I, food consistent with the prescribed
diet plans and equating to approximately 25% of the
participants energy requirements is given to the families.
During this phase physical activity advice is standardised
and delivered by the trial dietitian. The advice is consis-
tent with Australian recommendations for children and
adolescents including promoting an increase in inciden-
tal activity, a decrease in sedentary behaviour and an
increase in active transport [41].
During this phase the participants and at least one
parent/carer are expected to attend four face to face
meetings with the dietitian as outlined in Figure 1. In
addition to the face to face contact the dietitian also
makes contact with the participant using either phone,
email or text message, depending on the preference of
the participant. This contact is aimed at the participant
to assist with motivation and answer questions. It may
or may not involve the parent/carer.
Phase II: Intensive exercise program (4 to 6 months)
Phase II assesses the impact of a supervised, general
exercise program on the treatment effect of diet
and metformin. All participants receive an exercise
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Figure 1. The exercise program is conducted in small
groups for 1 hour, twice a week for 12 weeks in a com-
mercial gym, Fitness First. Participants are given free
access to Fitness First gyms in the geographic area in
w h i c ht h e yl i v e .T h eg y mp r o g r a mc o n s i s t so fac i r c u i t
training program with an age-appropriate mix of resis-
tance exercises and aerobic stations conducted by a qua-
lified physical trainer. In addition to the gym program
participants are encouraged to exercise once a week at
home. During this phase the trial dietitian offers support
to the participants every 4 weeks, Figure 1.
Phase III: Maintenance (7 to 12 months)
During Phase III participants are managed by their usual
physician or study physician and followed up by the trial
dietitian as indicated in Figure 1. They are encouraged
to continue with their diet and exercise regimens and
metformin (if required).
Training the dietitians (lifestyle coaches)
Two dietitians are employed to specifically to work on
this trial. Training of these dietitians to deliver the inter-
ventions is provided by two other experienced dietitians
(SB/KC) with expertise in lifestyle counselling in chil-
dren and adolescents with insulin resistance and predia-
betes. Training includes shadowing in the hospital
setting in order to gain experience and supervision is
received on a regular basis, approximately 6 weekly
intervals, as per department guidelines for training of
dietitians.
Blinding
Assessors of the main outcome measures are blinded to
treatment allocation. These include the two trial clinical
nurse consultants responsible for undertaking the
OGTTs and anthropometric measures, the technician
who takes the dual energy x-ray absorptiometry (DXA)
measurements and the primary and study physicians.
Measurements
Details of measurements are outlined below and the
measurement schedule is shown in Table 2.
Clinical Assessment
Family background and family medical history
Demographic and family medical history information is
collected at baseline by the study physician.
Anthropometry Weight and height are measured using
standard procedures [42]. For weight a single measure-
ment, measured to the nearest 0.1 kg, is recorded and
used for data analysis. Height is measured twice, to the
nearest 0.1 cm, and the average value is used for data
analysis. Waist circumference is measured to the nearest
0.1 cm using a flexible steel tape. The waist is defined
as the horizontal distance around the umbilicus using
the left hand under technique. The average of three
Table 1 Representative menu for the two diets
Diet 1 High carbohydrate, low fat Diet 2 Moderate carbohydrate, increased protein
Breakfast 2 breakfast (Weet-Bix) biscuits 1 slice of wholemeal toast
200 mL low-fat milk 1 tsp margarine
1 tsp honey 1 egg
1 piece fruit 1 piece fruit
Morning Tea 200 mL low-fat flavoured milk 200 g low-fat yoghurt
30 g muesli bar 1 piece fruit
Lunch 2 slices wholemeal bread 2 slices wholemeal bread
1 tsp margarine 1 tsp margarine
Unlimited salad vegetables 50 g lean meat
1 piece of fruit Unlimited salad vegetables
Afternoon tea 2 slices wholemeal bread toasted 4 wholegrain cracker biscuits
4 tsp peanut butter 1 slice reduced fat cheese
Dinner 1 cup cooked pasta 150 g beef steak
100 g meat & tomato based sauce 1 potato mashed
1 cup (or more) mixed vegetables/salad 1 cup (or more) mixed vegetables/salad
Supper 2 scoops low-fat ice cream 200 mL reduced-fat milk
1 cup strawberries 1 tbs Milo
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height ratio will be used as a measure of central adipos-
ity [43].
Pubertal status Pubertal status is categorised according
to the Tanner Scale after assessment by the study physi-
cian [44].
Blood Pressure Blood pressure is measured using an
automated blood pressure monitor (Dinamap 1846 SX)
according to standard procedures [45].
Acanthosis nigricans Acanthosis nigricans in the axilla
and neck is graded by the study physicians using the
Burke scale [46].
Body composition
Dual energy x-ray absorptiometry (DXA) DXA (Prod-
igy, Lunar-GE, Madison, WI USA) equipped with pro-
priety software version 8.6 is used to measure body
composition. The manufacturer recommended scan
mode (as determined by height and weight) is used for
total body mass measurements. When possible, standard
positioning techniques is used. Where the participant
width exceeds maximum scan width, subjects are
“mummy wrapped”, with arms placed in a lateral posi-
tion to reduce subject width. Scans are analysed using
manufacturer recommended techniques. In subjects
where delineation of body subregions is compromised
due to overlapping of tissue from two regions, lines are
positioned midway through the intersection of the two
regions.
Metabolic measures
OGTT An OGTT is performed after an overnight fast.
The dose of glucose is 1.75 g/kg of body weight to a
maximum of 75 g. Plasma glucose and insulin is sampled
every 30 minutes for 2 hours as previously described [38].
Blood samples In addition to glucose and insulin, blood
drawn at time 0 (OGTT) is analysed using standard
techniques for full blood count, lipids (total cholesterol,
HDL-C, triglycerides,), hs-CRP, oestradiol, testosterone,
sex hormone binding globulin, lactate, hepatic transami-
nases (alanine aminotransferase, gamma-glutamyl trans-
ferase), renal function tests (urea, electrolytes, and
creatinine). Blood (plasma and serum) is stored at -80°C
in the Institute of Endocrinology and Diabetes, CHW
for future analysis of homocystine (plasma), adipokines
and vitamin B12.
Urine samples Spot urine samples are collected and
analysed for albumin to creatinine ratio using standard
techniques.
Diet: Self monitoring, intake and eating behaviours
Diet checklist Seven day diet checklists are completed
by the participants for self monitoring, with assistance
from the parent or guardian if required. The checklists
were adapted from those used in previous studies [9].
Dietary 24 hour recall Dietary intake is assessed using
a methodology adapted from USDA five pass method as
used in the 2007 Australian National Children’sN u t r i -
ent and Physical Activity Survey [47]. In brief, at each
time point (weeks 9, 12, 26, 38 and 52) food and bever-
age intake is measured using a three pass 24 hour diet-
ary recall. To assist with estimation of portion sizes a
food model book is provided with picture guides of
common household measures and life size images,
plates, bowls, glasses and amorphous dishes.
Table 2 RESIST Measurement Schedule
Measurement Baseline 3 months 6 months 9 months 12 months
Clinical Assessment
Anthropometry ✓✓ ✓ ✓
Blood pressure ✓✓ ✓ ✓
Pubertal staging ✓✓ ✓ ✓
Acanthosis nigricans grading ✓✓ ✓ ✓
Body composition
Dual energy x-ray absorptiometry ✓✓ ✓
Metabolic Measures
Oral glucose tolerance test ✓✓ ✓
Fasting blood sample ✓✓ ✓ ✓
Urine sample (spot) ✓✓ ✓ ✓
Diet: Self monitoring, intake and questionnaires
Dietary checklist and questionnaires ✓✓ ✓
24 hour recall ✓✓✓ ✓
Physical activity, sedentary behaviour and fitness
CLASS questionnaire ✓✓ ✓ ✓
Fitness testing ✓✓ ✓
Metformin adherence
Pill count ✓✓✓ ✓
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Eating Pattern Inventory for Children [48].
Qualitative aspects of the diet Qualitative aspects of
the diet including, perceptions of cost, satiety, ease of
compliance are assessed by a locally developed question-
naire. This questionnaire is completed by the parent or
guardian.
Physical activity, sedentary behaviour and fitness
Physical activity and sedentary behaviour The Chil-
dren’s Leisure Activities Study Survey (CLASS) is com-
pleted by the participant with assistance from the parent
or guardian if required. CLASS assesses a range of phy-
sical activity and sedentary behaviours. CLASS has been
validated for use among children, and used by adoles-
cents aged 13-16 years in the Nepean Study [49]
Fitness Assessment of aerobic fitness is performed using
a Bruce treadmill protocol and breath by breath gas ana-
lysis. VO2 peak (maximal oxygen uptake) is expressed
relative to body mass [50].
Metformin compliance
Metformin adherence is assessed by pill counts by the
clinical trials pharmacist at CHW.
Data analysis
Data analyses will be carried out according to a pre-
established plan, with the primary analysis based on
intention to treat and with statistical support from the
Clinical Epidemiology Unit, CHW. Analysis will be
undertaken blinded, at the end of each phase of inter-
vention. Generalised linear models using a repeated
measures option will be used to assess differences in
continuous variables between baseline and follow up by
treatment group after adjusting for baseline covariates if
necessary [51]. Mixed models will also be used to inves-
tigate changes over time. The mixed models procedure
will take into account within subject correlations and
missing data points. A time by group interaction will be
included to investigate whether rates of change of adip-
osity and other primary outcomes are significantly dif-
ferent between the two study groups. In addition, the
proportions of young people who were successful in
decreasing adiposity will be compared between groups
and the result expressed as number-needed-to-treat.
Discussion
Clinical insulin resistance and prediabetes in the paedia-
tric population are rapidly emerging clinical problems
with serious health outcomes. With appropriate man-
agement these conditions are potentially reversible or at
least their progression can be delayed. This research
study is the first trial designed to provide definitive data
on the effective dietary management for this cohort.
This is crucial information to prevent metabolic compli-
cations, type 2 diabetes and early cardiovascular disease.
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